James Christensen, DO
Sports Medicine · Idaho Falls, IDNPI 1295094217
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 38 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by AbbVie at 43.1% of the total. That places this record below the midpoint for sports medicine clinicians in ID, where the typical reported total is $754.
Across 38 payments — averaging $19.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$313
- Amgen$83
- Trice Medical, Inc.$60
- Fidia Pharma USA Inc.$46
- AstraZeneca$43
- Actelion Pharmaceuticals US, Inc.$37
- plus $142 from 9 others
What the payments were for
- Food & beverage$724100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 16 | $313 |
| Amgen | 4 | $83 |
| Trice Medical, Inc. | 1 | $60 |
| Fidia Pharma USA Inc. | 3 | $46 |
| AstraZeneca(2 entities) | 3 | $43 |
| Actelion Pharmaceuticals US, Inc. | 2 | $37 |
| Averitas Pharma Inc. | 1 | $21 |
| Edwards Lifesciences | 1 | $20 |
| Nestle Healthcare Nutrition Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $13 |
| Mylan Specialty L.p. | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
How this compares
$724 in reported general payments places this provider in the 45th percentile of 33 sports medicine providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Celecoxib | 11 | $441 |
| Gabapentin | 13 | $266 |
| Atorvastatin Calcium | 15 | $178 |
| Levothyroxine Sodium | 27 | $171 |
| Escitalopram Oxalate | 17 | $84 |
| Omeprazole | 11 | $77 |
| Amlodipine Besylate | 13 | $41 |
| Losartan Potassium | 21 | $40 |
| Meloxicam | 13 | $26 |
| Lisinopril | 12 | $18 |
Paid to pharmacies, not to this prescriber.
Other sports medicine in Idaho Falls
- Jason DallingIdaho Falls$1K
- Joseph LiljenquistIdaho Falls$1K
- Cali Perez-VerdiaIdaho Falls$41
- Nathan GrimmBoise$23K
- Aaron NewtonNampa$18K
- John JelinekLewiston$13K
- Michael GustavelBoise$12K
- Arvin AlexanderKetchum$10K
- Jennifer MillerBoise$9K
- Richard RadnovichBoise$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.